Detalhe da pesquisa
1.
Therapeutic activity of GARP:TGF-ß1 blockade in murine primary myelofibrosis.
Blood
; 141(5): 490-502, 2023 02 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36322928
2.
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms.
Blood
; 141(8): 917-929, 2023 02 23.
Artigo
Inglês
| MEDLINE | ID: mdl-36356299
3.
Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants.
Blood
; 133(25): 2669-2681, 2019 06 20.
Artigo
Inglês
| MEDLINE | ID: mdl-30902807
4.
Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling.
J Allergy Clin Immunol
; 144(1): 224-235, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-30707971
5.
Degrading JAK2 in ALL by ruxolitinib-based PROTACs.
Blood
; 138(23): 2301-2302, 2021 12 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34882211
6.
Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia.
Blood
; 128(10): 1418-23, 2016 09 08.
Artigo
Inglês
| MEDLINE | ID: mdl-27389715
7.
Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
Blood
; 127(10): 1317-24, 2016 Mar 10.
Artigo
Inglês
| MEDLINE | ID: mdl-26608331
8.
An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L.
Blood
; 128(26): 3146-3158, 2016 12 29.
Artigo
Inglês
| MEDLINE | ID: mdl-28034873
9.
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Blood
; 127(10): 1325-35, 2016 Mar 10.
Artigo
Inglês
| MEDLINE | ID: mdl-26668133
10.
Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.
Blood
; 123(9): 1372-83, 2014 Feb 27.
Artigo
Inglês
| MEDLINE | ID: mdl-24398328
11.
Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation.
Proc Natl Acad Sci U S A
; 110(7): 2540-5, 2013 Feb 12.
Artigo
Inglês
| MEDLINE | ID: mdl-23359689
12.
Orientation-specific signalling by thrombopoietin receptor dimers.
EMBO J
; 30(21): 4398-413, 2011 Sep 02.
Artigo
Inglês
| MEDLINE | ID: mdl-21892137
13.
Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms.
Blood
; 132(25): 2695-2699, 2018 12 20.
Artigo
Inglês
| MEDLINE | ID: mdl-30377194
14.
Impact of isolated germline JAK2V617I mutation on human hematopoiesis.
Blood
; 121(20): 4156-65, 2013 May 16.
Artigo
Inglês
| MEDLINE | ID: mdl-23535062
15.
Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.
Blood
; 119(20): 4625-35, 2012 May 17.
Artigo
Inglês
| MEDLINE | ID: mdl-22378845
16.
Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.
J Cell Mol Med
; 17(11): 1397-409, 2013 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-24251790
17.
Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.
Biochem Soc Trans
; 41(4): 1048-54, 2013 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-23863177
18.
Mining for JAK-STAT mutations in cancer.
Trends Biochem Sci
; 33(3): 122-31, 2008 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-18291658
19.
Constitutive activation and oncogenicity are mediated by loss of helical structure at the cytosolic boundary of thrombopoietin receptor mutant dimers.
Elife
; 122023 Jun 20.
Artigo
Inglês
| MEDLINE | ID: mdl-37338955
20.
Oncogenic CALR mutant C-terminus mediates dual binding to the thrombopoietin receptor triggering complex dimerization and activation.
Nat Commun
; 14(1): 1881, 2023 04 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37019903